Please login to the form below

Not currently logged in

J&J profit falls on recall woes

Johnson & Johnson has reported a 23 per cent decline in profit for Q1 2011 in spite of increased revenues, as the company experienced high costs related to product recalls and lawsuit
Johnson & Johnson (J&J) has reported a 23 per cent decline in profit for the first quarter in spite of increased revenues, as the company experienced high costs related to product recalls and lawsuits.  

The company's revenue rose 3.5 per cent to $16.17bn for the quarter. Net income was $3.48bn, or $1.25 per share, down from $4.53bn, or $1.62 per share, in 2010's first quarter, when results were positively affected by a $910m gain related to litigation.

Consumer product sales were down 2.2 per cent to $3.68bn, largely due to the recalls. Prescription drug revenue was up 7.5 per cent globally to $6.1bn, while revenue from medical devices and diagnostics rose 3.3 per cent, to $6.43bn.

"Our pharmaceuticals business demonstrated strong operational sales growth this quarter of over 6 per cent, due to the success of our recently launched products such as Stelara and Simponi and core medicines such Remicade and Prezista," J&J chief financial officer Dominic Caruso said during a conference call. 

"And our consumer healthcare business saw sequential improvements in its operational sales growth versus the fourth quarter of 2010 in various markets, excluding the impact of the plant shutdown and the lower production levels in our McNeil US over-the-counter (OTC) business, where we are making good progress in addressing the manufacturing and quality issues in that business," he added. 

J&J also increased its estimate of costs per share related to recalls this year. "We had previously included in our guidance for 2011 an impact of approximately $0.06 per share from of the ongoing remediation efforts at McNeil," Caruso said. 

"Now that we have finalised the terms of the Consent Decree, we estimate that, that impact will be twice that amount. This results from both the slowdown in sales reflecting the impact on production volumes as we implement the additional quality steps outlined in the Decree, as well as additional investments required in the remediation process."

J&J raised its profit forecast for the year by 10 cents to $4.90 to $5 per share.

20th April 2011


PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...